Did You Miss Out on Nvidia and Micron Technology? This Super Semiconductor Stock Could Soar Over the Next Few Years.

Cohu is expanding production capacity at its Malaysia facilities, targeting a doubling by the end of 2026, to meet AI-driven demand for semiconductor test, handling, inspection, and metrology equipment. Wall Street expects 2026 revenue to rise 35% to $612 million, accelerating from 13% growth in 2025, while its high-performance-computing sales pipeline increased to $850 million from $750 million earlier in the year. The stock has gained 188% year to date, but trades at an estimated 70.5x 2026 adjusted EPS of $0.95; consensus expects EPS to nearly double to $1.85 in 2027, reducing the forward P/E to 36.2x.

Analysis

COHU is a higher-beta way to express AI semiconductor complexity, but its economics differ materially from NVDA or MU: test-and-inspection demand is driven by unit volumes, package complexity, qualification cycles, and customer capex timing rather than chip ASPs. The likely second-order beneficiaries are advanced-test peers Teradyne (TER), FormFactor (FORM), and Japan-listed Advantest (6857), while outsourced assembly/test providers Amkor (AMKR) and ASE Technology (ASX) gain if leading-edge packaging bottlenecks push more test content downstream. The key question is whether COHU can convert design-ins into repeatable platform revenue rather than one-off tools.

The near-term setup is unfavorable for chasing after a near-tripling move: the valuation already requires a sharp earnings ramp, leaving little tolerance for delayed customer qualifications or Malaysia capacity execution. A sales pipeline is not backlog; conversion probability, order timing, cancellation terms, gross-margin mix, and customer concentration are the missing diligence items. Over the next 1-3 months, bookings, book-to-bill, and commentary on HBM/GPU test utilization matter more than revenue; over 6-18 months, gross-margin expansion and sustained free-cash-flow conversion determine whether the multiple can remain elevated.

Contrarian view: AI test demand may be structurally real but the market could be over-attributing it to COHU specifically. Large customers typically dual-source critical test equipment, and dominant test vendors can use installed-base service, software, and financing advantages to defend accounts. A semiconductor capex pause would hurt COHU disproportionately because a small-cap equipment supplier with uneven profitability typically sees both estimate cuts and multiple compression simultaneously.

Key Decisions for Investors

• Do not chase COHU momentum before the next earnings release; place it on a watchlist for an entry only if orders/backlog visibly convert and management raises the following-year revenue or margin framework. Thesis is invalidated by a sequential bookings decline, lower utilization commentary, or a qualification delay from a major customer.
• For AI-test exposure, favor a 6-12 month pair trade: long TER or FORM versus short COHU in equal dollar amounts. This retains exposure to rising test intensity while reducing the risk that COHU's valuation embeds an overly optimistic conversion rate; reassess if COHU demonstrates two consecutive quarters of accelerating bookings and margin expansion.
• If COHU sells off 20-25% on a timing-related miss without deterioration in pipeline conversion, consider a small starter long with a 12-18 month horizon and a defined stop on reduced annual guidance. Upside requires earnings power to approach the out-year consensus trajectory; downside is material if the market re-rates the shares toward a cyclical equipment multiple.
• Monitor AMKR and ASX quarterly advanced-packaging utilization and capex as external validation. Improving outsourced test/package demand alongside COHU order growth supports the thesis; divergence would indicate share loss, customer-specific qualification friction, or premature AI-capex expectations.